Extended drug trial aims to keep transplant Patients' blood counts stable
NCT ID NCT05509582
Summary
This was a follow-up study for people who had a stem cell transplant and then developed low blood cell counts (cytopenias). It aimed to see if taking the drug fostamatinib long-term (up to 21 more months) could safely help them maintain healthier levels of red blood cells or platelets. The study was only for people who had already responded well to fostamatinib in a previous 12-week trial. However, this extension study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.